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ABSTRACT 
 
 The production of monoclonal antibodies (mAbs) is fast becoming a staple of 
pharmaceutical development. Understanding how differing feeds and bioreactor setups 
affects the production of mAbs is important for improving yields. In the process of 
manufacturing mAb IPTG1, an anti-phosphotyrosine antibody produced at Millipore, this 
project monitored cell viability and secreted antibody yields under a variety of culture 
conditions, including different media feeds and different gas spargers. 
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BACKGROUND 
 
 
 Since the development of the first cultured mammalian cell line in 1952, cell 
culture and the bioprocess industry have grown enormously. Increased knowledge of 
biology has facilitated pharmaceutical advancements and scientific research, especially in 
the production of monoclonal antibodies (mAbs) for targeting specific proteins (Bakalar, 
2012).  The cells, methods, and biological products are all important aspects of the 
process of bioproduction.   
 
Bioprocessing 
 According to the Commission on Life Sciences (1992), Bioprocess engineering 
can be defined as “…the sub-discipline within biotechnology that is responsible for 
translating the discoveries of life science into practical products, processes or systems 
that can serve the needs of society.”  A wide variety of products have been manufactured 
using bioprocess engineering, but the best characterized is the biopharmaceutical. The 
FDA first approved a biopharmaceutical created from mammalian cells in1986 for 
Muromonab CD3, an immunosuppressant drug given to reduce acute rejection in patients 
with organ transplants (Emmons and Hunsicker, 1987). 
Bioprocessing begins with the adaptation of a specific biological function to 
produce a protein or other biological molecule of choice. Today, a common method of 
bioproduction is to attach a gene of interest to a selectable marker, such as an antibiotic 
resistance gene or dihydrofolate reductase, to allow the selection of cells containing the 
recombinant DNA (rDNA). Cells that have not successfully integrated the gene of 
interest usually do not survive the selection agent (Chusainow et al., 2009).  Once a stable 
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cell clone has been developed containing the rDNA, the cells are expanded to produce the 
molecule of interest.  The expansion usually begins in a simple flask, and then proceeds 
to larger scale bioreactors – devices designed to grow larger cultures of cells to produce 
significant amounts of the product (Bioreactor, 2013). 
 
Bioreactors 
Bioreactors are used to grow large amounts of cells in a controlled environment 
produce a product. The modern bioreactor comes in sizes ranging from benchtop 3 liter 
reactors, to industrial reactors that can hold over 10,000 liters of culture (Plunkett, 2011). 
All bioreactors have a few basic requirements: a sterile environment, a way to provide 
necessary cellular nutrients, a system to monitor the conditions inside a culture, and a 
means to stimulate the cells to produce product. 
 First and foremost, a sterile environment is very important to the health of the 
culture. Mammalian cells are grown in a rich medium that is highly susceptible to 
contamination by outside organisms. These contaminants will deprive nutrients from the 
growing cells, either making it more difficult to produce the protein product needed or 
choking out the productive cells. Most reactors are sterilized before use by autoclaving, 
however some companies have moved on to single-use reactors to remove that necessity.  
Nutrients and gases are also added to the reactor using a sterile approach. Necessary 
gasses depend on the type of cell, but often include: air, oxygen, or nitrogen for cell 
health, and carbon dioxide to help control the pH of the reactor. Gases typically pass 
through sterile filters on their way into the reactor, and will also often pass through a type 
of sparger to release gases into the culture itself, rather than direct absorption through the 
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liquid surface. Two common sparger types are sintered and open pipe; each has their pros 
and cons. Sintered spargers release smaller bubbles which allow faster absorption, 
however the size of the bubbles produced can be fatal to cells. Open pipe spargers require 
more gas flow for oxygen absorption, but they tend to produce less cell shear (Sieblist et 
al., 2011).  
Cells are sometimes provided with nutrients or glucose feeds during bioreactor 
runs. These depend on the process and are developed based on the needs of the cells. The 
addition of gasses and nutrients to a reactor, and the growth of the cells, changes the 
conditions inside the vessel. The changing environment must be monitored.  Bioreactor 
systems are connected via computers and probes to monitor pH, dissolved oxygen, 
temperature, and other variables.   
Finally, depending on the type of cultured cell, reactors may need to be agitated to 
prevent clumping, cell death, and lackluster growth. There are a variety of ways to 
accomplish this, however the most common uses a stirred tank reactor. Using an agitator, 
a stirred tank reactor allows for equal distribution of nutrients and cells, and prevents the 
clumping of suspension culture (Sieblist et al., 2011). 
 A variety of different strategies are used to ensure bioreactors produce the highest 
levels of protein possible. The most basic of these is the feed strategy.  
 
Feed Strategies 
There are three major feed strategies for bioprocess in bioreactors: batch culture, 
fed-batch culture, and perfusion (Hu et al., 2011).  The batch culture strategy provides all 
nutrients in the initial media provided to the cells. While this makes the process much 
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simpler than fed-batch or perfusion and reduces the risk of contamination to the reactor, 
the limited amount of nutrients prevents the cells from achieving their maximum 
production ability. Fed-batch cultures allow a set amount of nutrients added to the 
cultures as they are growing which allows for cells to grow to higher densities and to 
increase product yield (Hu et al., 2011).  Fed-batch is much simpler than perfusion 
culture. Perfusion culture completely replaces the media of the reactor with a continuous 
feed throughout the growth process. This allows the reactor to be run indefinitely, 
however it is not a simple or realistic approach for labs with limited resources. It is also 
more difficult to scale up (Whitford, 2006).  Often the conditions in a bioreactor are 
initially simulated in a shake flask study to determine the optimal feed strategy and 
expected growth of the cells.  
Once the reactors are grown to the optimum cell density, the protein product of 
interest is purified from the culture or medium.  This is known as downstream bio-
proccessing. But before this process can begin, there needs to be confirmation of the 
protein being produced.  
 
Chinese Hamster Ovary Cells 
Chinese Hamster Ovary (CHO) cells are a widespread cell type frequently used in 
mammalian cell culture and bio-production. These cells were first isolated for use in 
mammalian culture from an ovary of a Chinese hamster in 1957 by Dr. Theodore T. 
Puck. Since then, they have widely been utilized to produce antibodies and other proteins 
for therapies of a variety of different ailments (Jayapal et al., nd). In fact, 70% of 
therapeutic recombinant proteins on the market have been estimated to be made in CHO 
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cells (Kim et al., 2012).  These cells are advantageous for many reasons, including their 
resiliency and ability to grow in both suspension and adherent cultures. However, what 
may be their most valuable characteristic is the DHFR gene deficiency in some mutant 
strains (Wurm and Hacker, 2011).  The purpose of the DHFR gene (dihydrofolate 
reductase) is to convert dihydrofolate to tetrahydrofolate, allowing CHO cells to 
synthesize specific amino acids (NCBI, 2013).  In some CHO cell lines, the DHFR gene 
is inactive, making it difficult for the cells to effectively utilize such nutrients as purine, 
pyrimidine, or glycine. When rDNA encoding a desired product is transformed into 
DHFR-mutant cells, the gene of interest is attached to a DHFR gene.  Only cells 
receiving WT DHFR from the rDNA construct will be survive on the selection medium 
(Camire, 2000).  This method of selection provides a powerful way for scientists to 
transform DNA into cells and select for the recombinants.  
 
Monoclonal Antibodies 
 Antibodies are an essential part of the mammalian immune system. These proteins 
bind to foreign proteins and cells such as bacteria and viruses, and trigger an immune 
response throughout the body. Each antibody detects a specific antigen, thus allowing for 
a very precise response (Bakalar, 2012).  The monoclonal antibody (mAb) is a very 
common product of mammalian cell culture and bioproduction. The term monoclonal 
antibody refers specifically to an antibody derived from a single B-cell clone, so it has 
one type of specificity.  mAbs are made in a laboratory. The first mAbs designed 
specifically for treatment of human diseases were developed in the early 1980s (Emmons 
and Hunsicker, 1987).  Since then, the mAb industry has grown exponentially.  As of 
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2010, there were seven approved mAb drugs on the market and over 130 more in clinical 
trials. The current approved mAbs treat diseases ranging from rheumatoid arthritis and 
lupus to melanomas (Nelson et al., 2010).  mAbs are not just used for treating diseases 
however, they can also be used for diagnostic tests, and biological study.  
 The structure of the mAb (Figure-1) is very important for understanding how to 
use and confirm the presence of an antibody in a bioprocess culture. Antibodies are made 
of two identical strands known as heavy chains (green in the figure) and two identical 
light chains (yellow). These chains are bound together with disulfide bonds.  
 
 
 
 
 
 
 
 
 
Figure-1: Diagram of a Typical Antibody.  The structure is composed of two heavy chains 
(green) and two light chains (yellow), held together by disulfide bonds.  (Janeway et al., 2001) 
 
 Y-shaped structure is integral to the functioning of each antibody, as it allows for 
binding to a specific antigen, while also permitting the antibody to bind to other 
antibodies and molecules to make higher order complexes.  This characteristic is often 
exploited for scientific research and other applications (Janeway et al., 2001). Protein-A, 
a surface protein found in specific bacteria, readily binds to antibodies, so scientists 
frequently use Protein-A to both purify and quantify antibodies.  
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PROJECT PURPOSE 
 
The purpose of this project is to prove that altering bioreactor feeds based on the 
analysis of cells and byproducts can increase the yield of a test mAb (IPTG1) being 
produced at Millipore Corp.  This goal was accomplished by comparing cell viability and 
secreted antibody titers for various bioreactor feeds and gas spargers.  
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METHODS 
 
Bioreactor Setup 
CHO cells were thawed two weeks prior to use in Cellvento 200 chemically 
defined culture medium (Merck Millipore) supplemented with 4 mM glutamine and 20 
μM puromycin. The puromycin is used as a selection agent to ensure all the cells are 
producing the desired antibody. Cells were passaged twice a week until they reached the 
necessary density, carefully keeping the cells in growth phase during this time, as 
overgrown cells tend to lag once added to a reactor.  
The setup of a single-use stirred tank bioreactor varied from process to process. 
The reactors used were Mobius CellReady 3L single-use bioreactors. Reactors were 
completely set up the night before with 2 liters of Cellvento 200 medium and 4 mM 
glutamine. All the settings used for each reactor run are shown below in the table.  
 
Temperature 
 
Agitator 
Speed 
pH Set 
Point 
DO Set 
Point 
Sparger 
Air Flow 
Rate 
Oxygen 
Flow 
Rate 
Run 1 36.8°C 180 RPM 7 50% Open Pipe 
0-100 
mL/min 
0-100 
mL/min 
Run 2 36.8°C 180 RPM 7 50% Open Pipe 
0-100 
mL/min 
0-100 
mL/min 
Run 3 36.8°C 180 RPM 7 50% 
Sintered 
Sparger 
0-100 
mL/min 
0-25 
mL/min 
 
 
The setup serves two purposes: 1) bring the medium up to running temperature and O2 
concentration, and 2) ensure the medium in the reactor was not contaminated by poor 
autoclaving of the DO or pH probes. The following day, the reactors were seeded at 0.5 x 
10
5 
cells per ml. Prior to being added to the reactor, cells were counted using a Beckman 
Coulter ViCell.  
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Feed Strategy 
The bioreactors were fed according to the CellVento 200 guidelines. This requires 
three different feeds per reactor: a CellVento feed, a mixed supplements feed, and a 
cystine tyrosine feed.  All reactors were fed on days 3, 5, 7 and 10 with all three feeds. 
Glucose was checked and supplemented when needed to maintain a concentration of 4 
grams per liter. Over the course of the experiment, both the CellVento feed and the 
cystine tyrosine feed were modified to produce better growth and mAb titers in the 
reactors.  
 CellVento 200 Feed 
Mixed Supplements 
Feed 
Cystine/Tyrosine 
Feed 
Day 3 30 ml/L 3 ml/L 5.3 ml/L 
Day 5 60 ml/L 6 ml/L 5.3 ml/L 
Day 7 60 ml/L 6 ml/L 5.3 ml/L 
Day 10 60/ml/L 6 ml/L 5.3 ml/L 
 
Bioreactor Sampling  
Reactors were sampled twice a day.  A 3 milliliter purge was done using the 
sampling port and then 5 milliliter sample was withdrawn.  This sample is immediately 
run on the Nova Biomedical BioProfile FLEX analyzer to accurately measure the carbon 
dioxide and oxygen concentrations. Following that, the sample was diluted 1 to 2 with 
accumax de-clumping agent, and the sample was run on the vicell in order to accurately 
count cell density and viability. The remaining portion of sample was spun down at a 
high speed for 5 minutes, and the supernatant which contained the secreted mAb product, 
was collected then placed in a -20°C freezer until titer measurements could be completed. 
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Measurement of mAb Titer 
 The antibody titer of the reactors was measured after each run was completed. 
This was measured using a ForteBio Octet instrument which uses Protein A sensors to 
quantify the amount of antibody present in the supernatant. First, medium was added to 
all the wells in column A of a 96 well plate to serve as a blanking solution for the assay. 
An antibody standard curve was created in the next two rows with known concentrations 
of IPTG antibody which was purified in-house. The medium samples were diluted and 
added to the wells. This assay was run using protein-A sensors and the direct 
quantification program on the instrument.  
 
15 
 
RESULTS 
 
 
This project investigated whether altering bioreactor feeds based on the analysis 
of cells and by-products can increase the amount of a test mAb (IPTG1) produced.  This 
was accomplished by comparing various bioreactor feeds while monitoring cell viability 
and antibody titers.  Single-use 3-liter stirred tank bioreactors were used.  Reactors 1 and 
2 were set up identically (duplicates) at 36.8°C, 180 rpm stirring, 7.0 pH set point, 
dissolved O2 set at 50%, Open pipe type gas sparger, 0-100 ml/min air flow rate, and 0-
100 ml/min O2 flow rate. 
Using the commercially available feeds and growth medium discussed in 
Methods, a control run of reactors 1 and 2 was completed.  Figure-2 shows the cell 
viability and viable cell yield, while Figure-3 shows the antibody yields.  This initial run 
was performed to serve as a baseline in order to optimize cell viability and density for 
future runs with modified feeds. The data indicate that the cell viability, viable cell 
density, and antibody yields were very consistent between the two identical runs.  Cell 
viability (solid curves) remained near 100% until around day-10 and then dropped 
slightly.  Viable cell density peaked around day-6 at approximately 12 million cells per 
ml.  IPTG antibody yields increased consistently throughout the runs, and peaked around 
days 10-11 at approximately 0.27 mg/ml. 
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Figure-2: Plot of Cell Viability and Viable Cell Density for 11 Days. Although the viability 
(solid lines) for both reactors 1 and 2 drops considerably at day 7, the viable cell density (dotted 
lines) reached above 12 million cells per milliliter at peak.  
 
 
 
Figure-3: Plot of Antibody Yield (mg/ml).  The yield was measured using a protein sensor in 
the octet assay. Both reactors reached a high of around 0.27 mg/ml of IPTG antibody.  
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Following the initial set of baseline reactors, a series of five different reactors 
were run with changes to their feeds: one control reactor, two reactors with a modified 
version of the CellVento 200 feed (referred to as modified feed A), and two reactors with 
a modified version of the CellVento 200 feed (referenced as modified feed B) (Figures 4 
and 5).  The reactors with the modified feeds were also run with double the normal 
amount of the cystine and tyrosine feed.   The viable cell density was highest for the 
control reactor, peaking at approximately 17 million cells per ml.  All other feed 
conditions produced approximately equal viable cell densities, slightly underneath the 
control reactor.  The antibody yields were also highest for the control reactor, reaching 
0.30 mg/ml at day-12.  Feed-B produced the next highest yield at around 0.25 mg/ml at 
day-10. 
 
 
Figure-4: Plots of Cell Viability and Viable Cell Density For Reactors With Different Feeds.  
The viable cell density (dotted lines) reached much higher in the control reactors as it did in the 
reactors with variable feeds.  
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Figure-5: Plot of Antibody Yields (mg/ml) For Runs with Different Feeds.  This graph of the 
reactor titer over tie also shows the control reactor made significantly more titer over time as 
well.  
 
 
During the final days of this second set of reactors, crystals of unknown origin 
were seen while running cell counts. These crystals are shown in Figure-6.  Because of 
the high levels of cystine added in the modified cystine tyrosine feeds, it was proposed 
that these crystals were cystine crystals forming after the nutrient had fallen out of 
solution. The presence of these crystals could explain the slower growth and lower 
viability of these reactors as the cells would be unable to take up the cystine in 
crystallized form. The crystals may also trap cells, killing them, which could have caused 
the lower viability. 
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Figure-6: Photo of Presumed Cystine Crystals.  Show is a photograph of crystals believed to 
be cystine precipitating out of the culture due to its high concentration. This picture is from Feed-
A Reactor-2, however similar crystals were found in all reactors besides the control reactor. Photo 
taken using Beckman Coulter Vicell.  
 
 
Another possible cause of the observed decreased viability and cell density of this 
reactor run was the high levels of carbon dioxide measured after the addition of the feeds 
(Figure-7). The cystine tyrosine feed reactor in particular had a very high pH, so CO2 
was added to the reactors to lower the pH, and was unable to be stripped away.   This 
resulted in a high percent CO2 in the reactors, seen in the figure. 
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Figure-7: Measured Percent CO2 in the Reactors With Different Feeds.  CO2 was added to 
lower the pH of the reactor. It was very high in the experimental reactors but remained at a 
reasonable level in the control reactor (blue dotted line).  
  
 
One final set of reactors was run with a control reactor and two different modified 
feed reactors all with the normal concentration cystine/tyrosine feed, and one reactor with 
normal feeds but a low concentration of cystine/tyrosine. A different gas strategy was 
tested using a sintered-type gas sparger instead of an open pipe to remove the carbon 
dioxide faster from the culture (Figures-8 and 9). As shown in Figure 8, the cell 
viability and viable cell density of all these reactors with the sintered sparger were lower 
than the previous runs with the pipe sparger, including in the control reactor. The mAb 
titer of the reactor (Figure 9) is also low, likely reflecting the low growth of the cells.  
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Figure-8: Plot of Cell Viability and Viable Cell Density Using a Sintered Type Gas Sparger.  
The solid lines measure the percentage of viable cells in the reactor, while the dashed lines 
measure the viable cell density.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-9: Plot of Antibody Yields Using a Sintered Type Gas Sparger.  The mAb yields were 
lower than with the other runs, most likely due to the low cell density caused by the sintered 
sparger.  
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DISCUSSION 
 
 Over the course of three sets of reactor runs, it can be seen that small changes in 
media feed or in CO2 content can make a great difference in the viability of the cells and 
the mAb yields.  The dramatic effect of changing the gas strategy using different spargers 
was unexpected. While the effect of sparger type has been seen previously in reactors, it 
had not been evaluated with this cell line in this media (Chalmers, 1994). Adding the 
high concentration of cystine tyrosine to the feed also had a drastic effect on the growth 
of the culture. This feed had a high pH, so it was added much slower than the other feeds 
to prevent cell death. However, the amount of CO2 added to counter the high pH was 
most likely more detrimental to the cells than the pH change would have been.  
In future runs, less CO2 will be added during feeding times, and the feeds will be 
added over the course of two hours rather than just one hour. This will hopefully allow 
less CO2 build-up in the reactor, as the pH will be less dramatic during feeds. The data 
gathered from the high cystine tyrosine run may not be as accurate as the other runs since 
nutrients were precipitating out of the media as crystals. A change in titer growth due to 
changes in feeds cannot be proven if the nutrients are not in solution.  
After optimizing the yield of antibody, in the future, western blots will be used to 
verify the produced antibody interacts with its cognate antigen and retains sufficient 
structure to be functional.   This will also help ensure that the reactor processes and the 
feed changes have not negatively affected the functional domains of the antibody.  
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